Drug Interaction Report
4 potential interactions and/or warnings found for the following 2 drugs:
- revumenib
- Symdeko (ivacaftor / tezacaftor)
Interactions between your drugs
ivacaftor revumenib
Applies to: Symdeko (ivacaftor / tezacaftor), revumenib
Information for this minor interaction is available on the professional version.
Drug and food/lifestyle interactions
ivacaftor food/lifestyle
Applies to: Symdeko (ivacaftor / tezacaftor)
Ivacaftor should be taken with fat-containing foods such as eggs, avocados, nuts, meat, butter, peanut butter, cheese pizza, and whole-milk dairy products to help with its absorption. Do not consume grapefruit juice or any food that contains grapefruit or Seville oranges during treatment with ivacaftor unless directed otherwise by your doctor. Grapefruit juice can significantly increase the blood levels of ivacaftor. This may increase the risk and/or severity of serious side effects such as liver damage. Call your doctor immediately if you have fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark urine, pale stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
tezacaftor food/lifestyle
Applies to: Symdeko (ivacaftor / tezacaftor)
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of tezacaftor, deutivacaftor, and vanzacaftor. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. In general, the effect of grapefruit juice is concentration-, dose- and preparation- dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. The risk and/or severity of serious side effects such as liver damage may be increased.
ADJUST DOSING INTERVAL: Administration with fat-containing food may increase the oral bioavailability of vanzacaftor and deutivacaftor. Administration with a fat containing meal increased vanzacaftor systemic exposure (AUC) by 4- (low-fat meal) to 6- (high-fat meal) fold. While deutivacaftor AUC increased approximately 3- (low-fat meal) to 4- (high-fat meal) fold, relative to administration in a fasting state. Tezacaftor exposure is not significantly affected by administration of fat-containing foods.
MANAGEMENT: Patients treated with tezacaftor, deutivacaftor, vanzacaftor -containing medications should avoid consumption of grapefruit juice and any food that contains grapefruit. To improve absorption, patients should be advised to take vanzacaftor and/or deutivacaftor containing medications with fat-containing foods such as eggs, avocados, nuts, meat, butter, peanut butter, cheese pizza, and whole-milk dairy products at approximately the same time of the day. A typical cystic fibrosis diet will satisfy this requirement.
revumenib food/lifestyle
Applies to: revumenib
High fat content meals may affect the absorption of revumenib. It is recommended that revumenib be taken while fasting or with a low fat meal (approximately 400 calories, with 25% of calories from fat). Grapefruit juice may also increase the blood levels of revumenib which can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). Increased levels of [CS1] may also increase the risk of developing a serious and potentially life-threatening condition called differentiation syndrome. Symptoms of differentiation syndrome include: fever, cough, shortness of breath, severe headache, confusion, dizziness, rapid weight gain, swelling, or decreased urination. You should seek immediate medical attention if you develop any of these symptoms and/or symptoms of QT prolongation such as sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with revumenib. The risk and/or severity of other side effects may also increase, including nausea, vomiting, diarrhea, fever or infections. You may need additional monitoring if grapefruit or grapefruit juice are consumed during treatment with revumenib. Talk to a healthcare provider if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Venclexta
Venclexta may be used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma ...
Vidaza
Vidaza is used to treat certain types of bone marrow cancers and blood cell disorders. Learn about ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Tibsovo
Tibsovo (ivosidenib) is a once-daily oral medication that targets a specific gene mutation called ...
Revuforj
Revuforj is used to treat acute leukemia with a lysine methyltransferase 2A gene translocation ...
Ivosidenib
Ivosidenib is used for acute myeloid leukemia, biliary tract tumor, myelodysplastic syndrome
Daunorubicin
Daunorubicin is used for acute lymphocytic leukemia, acute myeloid leukemia, acute nonlymphocytic ...
Azacitidine
Azacitidine is used for acute myeloid leukemia, myelodysplastic syndrome
Cytarabine
Cytarabine is used for acute myeloid leukemia, acute nonlymphocytic leukemia, chronic myelogenous ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.